4th Quarter - Report — NVG, LLC for BIOGEN (2013)

Firm

NVG, LLC

Client

BIOGEN

Income

$50,000

Expenses

—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Supply chain integrity (H.R. 3204 Drug Quality and Security Act and S. 959 Pharmaceutical Quality, Security, and Accountability Act); Newborn Screen Reauthorization (S. 1417)

Lobbyist	Covered position, as disclosed
LISA GERMAN FOSTER	—
ANDREA LARUE	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1417 (113th), H.R. 3204 (113th), S. 959 (113th)

Copyright/Patent/Trademark CPT

Patent Quality Improvement Act of 2013 (S. 866, H.R. 2766), Patent Abuse Reduction Act of 2013 (S. 1013, H.R. 2639); The Innovation Act (HR 3309); Patent Transparency and Improvements Act of 2013 (S. 1720); General issues related to intellectual property and potential changes to the patent system

Lobbyist	Covered position, as disclosed
ANDREA LARUE New	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2639 (113th), H.R. 2766 (113th), S. 1013 (113th), S. 866 (113th), S. 1720 (113th), H.R. 3309 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.